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Abstract: Biological markers for assessment of exposure to a variety of environmental carcinogens has been widely applied 
in both basic as well as clinical research. Exposure to tobacco smoke presents an ideal environment with which to develop, 
characterize, and reﬁ  ne biological markers, especially of those carcinogens found in tobacco. In the present study, a sensitive 
gas chromatography/mass spectrometry (GC/MS) method was developed to measure nitrosamine- hemoglobin adducts 
(HPB-Hb (4-Hydroxy-3-pyridinyl-1-butanone) at trace levels in red blood cells of both African-American and Caucasian 
smoking and nonsmoking mothers and their infants. Gas chromatographic and mass spectrometric methods with chemical 
ionization (CI) of methane reagent gas in both positive and negative ion mode as well as electron ionization (EI) were 
studied to determine differences in sensitivity of detection among the various ionization methods. Detection limits using 
both positive and negative chemical ionization modes were found to be 30 femtomoles of HPB, whereas detection using 
electron impact modes yielded a detection limit of 80 femtomoles of HBP. Comparative derivatization of HPB was performed 
using O-bis(Trimethylsilyl)-triﬂ  uoroacetamide (BSTFA) and 2, 3, 4, 5, 6-Pentaﬂ  uorobenzoylchloride (PFBC). Both Negative 
CI and Positive CI modes of analysis were compared to the more widely accepted EI modes of mass spectrometric 
analysis. 
Keywords: Biomarkers, Exposure, Nitrosoamine-hemoglobin adducts, Tobacco, Smoking, GC/MS.
Introduction
Smoking during pregnancy has been linked to a variety of adverse pregnancy outcomes, including low 
birthweight, spontaneous abortion, and infant death (Bajanowski, Brinkmann et al. 2007; Carter, Paterson 
et al. 2007; Jaddoe, de Ridder et al. 2007; Wilkinson and Walker, 2007). In addition, premature delivery 
(<36 weeks gestational age) has been linked to maternal smoking during pregnancy (Kolas, Nakling 
et al. 2000; Williams, Davenport et al. 2000; Raatikainen, Huurinainen et al. 2007). Some biological 
mechanisms which have been clinically conﬁ  rmed link cigarette smoke to fetal health and include an 
association between nicotine and decreased placental blood ﬂ  ow and an increase in fetal heart rate. Of 
the fetal outcomes documented, low birthweight shows the clearest and most consistent association 
with maternal smoking (Mathews, 2001; Wideroe, Vik et al. 2003; Dubois and Girard, 2006; Giglia, 
Binns et al. 2006; Maccabe, Martinsson et al. 2007; Ng and Zelikoff, 2007). Evidence suggests that a 
dose response relationship exists between cigarette consumption, especially during the third trimester 
and birth weight. The prevalence of smoking during pregnancy has been estimated at between 15 and 
30% of all pregnant women with the percentages varying slightly dependent on the source of the data 
used and with State-to-State variations (Kentucky generally ranks among the highest States in % of 
women smokers) (Pauly, Sparks et al. 2004; Bada, Das et al. 2005; Okoli, Kelly et al. 2007). Recently 
the Centers for Disease Control (CDC) reported that the incidence of State-speciﬁ  c smoking prevalence 
among U.S. adults varied widely ranging from a low of 14.2 percent in Utah to a high of 30.8 percent 
in Kentucky (Garcia-Rill, Buchanan et al. 2007; Mossey, Davies et al. 2007; Nigg and Breslau, 2007; 
Raatikainen, Huurinainen et al. 2007; Whitﬁ  eld, King et al. 2007). In addition, women with mistimed 
or unwanted pregnancies are more likely to smoke throughout pregnancy as are women that are single 
and of teenage years. Smoking cigarettes during pregnancy has been shown to increase the risk of 
numerous adverse pregnancy outcomes, including low birthweight, preterm delivery, miscarriage, 270
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ectopic (tubal) pregnancy, infant death, low Apgar 
scores, and early childhood illness (respiratory 
illness, asthma) (Chen, Wen et al. 2007; Mahe, 
Girszyn et al. 2007; Ng and Zelikoff, 2007; Okoli, 
Kelly et al. 2007; Silver, 2007)
The effects of tobacco exposure 
on neonatal growth and development
Prenatal tobacco exposure has been reported to 
be a signiﬁ  cant risk factor for sudden infant 
death syndrome and is estimated to be respon-
sible for up to 4,800 infant deaths as well as 
61,000 low-birth-weight infants and 26,000 
infants requiring neonatal intensive care annually 
(Yuan, Platt et al. 2005; Shah, Sullivan et al. 
2006; Bajanowski, Brinkmann et al. 2007; Bashiri, 
Lazer et al. 2007; Raatikainen, Huurinainen et al. 
2007). In a national survey of pregnant adult 
women, however, 20.4 percent reported smoking 
cigarettes during pregnancy. This proportion 
rises to about one-half for women in lower socio-
economic populations. Smoking during preg-
nancy is more prevalent among Caucasian 
women compared with African-American or 
Hispanic women (Bibby and Stewart, 2004; 
Chang, Selvin et al. 2006; Bell, Zimmerman 
et al. 2007; Benhadi, Wiersinga et al. 2007; 
Collins, David et al. 2007; Honein, Rasmussen 
et al. 2007). Caucasian women also smoke at 
higher levels than do women of other ethnicities. 
Women who smoke during pregnancy are less 
likely to be married, have less education, have 
lower incomes, and attend fewer prenatal visits 
compared with women who do not smoke during 
pregnancy (Singh and Kogan, 2007).
In a recent study of pregnant teenagers, more 
than one-half of whom were smokers, prenatal 
tobacco exposure was signiﬁ  cantly related to 
reduced birth weight, birth length, head circum-
ference, and chest circumference (Dewan, 
Brabin et al. 2003; Cornelius, Leech et al. 2004; 
Jones, Williams et al. 2004; Strinic, Bukovic 
et al. 2005; Leiner, Villa et al. 2007). These 
reductions were even more pronounced than 
those found in a similar cohort of the children 
of adult women. For example, in the study of 
adult mothers and their children, prenatal 
tobacco use was signiﬁ  cantly associated with a 
reduction in birth weight of 158 grams per pack 
per day. In the children of teenage mothers, 
prenatal tobacco exposure was significantly 
associated with a reduction in birth weight of 
202 grams per pack per day.
Carcinogens found in tobacco
Thousands of chemicals are known to exist in 
tobacco smoke. These compounds range from 
small molecules such as ethylene oxide, butadiene, 
and styrene, to larger molecules such as the poly-
cyclic aromatic hydrocarbons, tobacco speciﬁ  c 
nitrosamines, and aromatic amines (Hecht, 2004; 
Murphy, Link et al. 2004; Benowitz, Jacob et al. 
2005; Bernert, Jain et al. 2005; Sturla, Scott et al. 
2005; Carmella, Yoder et al. 2006; Hatsukami, 
Benowitz et al. 2006; Schwartz, Prysak et al. 2007). 
Cigarette smoking accounts for 30% of all cancer 
deaths in the United States with most of these 
deaths from lung cancer (Lippman and Spitz, 2001; 
Williams and Sandler, 2001; Fagerstrom, 2002; 
Hecht, 2003; Airoldi, Vineis et al. 2005). It has 
been established from numerous studies that ciga-
rette smoke contains more than 40 known or puta-
tive carcinogens (Husgafvel-Pursiainen, 2004; 
Wogan, Hecht et al. 2004; Lemmonds, Hecht et al. 
2005; Schwartz, Prysak et al. 2007). Many of these 
compounds have the potential because great harm 
in the developintg fetus and lead to unwanted 
effects after delivery. 
N-nitrosamines (as shown in Table 1), are gener-
ated by the nitrosation of nicotine during tobacco 
curing and smoking are among the most abundant 
and potent carcinogens in tobacco smoke 
(Hoffmann, Rivenson et al. 1991; Hecht, Carmella 
et al. 1993; Hoffmann, Brunnemann et al. 1994; 
Brunnemann, Prokopczyk et al. 1996; Razani-
Boroujerdi and Sopori, 2007). The tobacco speciﬁ  c 
N-nitrosamines NNN (N′-nitrosonornicotine) and 
NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone) are particularly strong carcinogens in 
adult laboratory rodents, with a wide range of 
carcinogenic activity including a relatively high 
potency in the respiratory tract (Hoffmann, 
Brunnemann et al. 1994). The tobacco speciﬁ  c 
nitrosamine NNK is one of the most important 
carcinogens in tobacco smoke and smokeless 
tobacco products (LaVoie, Stern et al. 1987; 
Hoffmann, Rivenson et al. 1991; Brunnemann, 
Prokopczyk et al. 1996) . This nitrosamine induces 
tumors of the lung, liver, nasal cavity, and pancreas 
in the rat. NNK is metabolically activated to reac-
tive species that binds to hemoglobin and to DNA 
(Husgafvel-Pursiainen, 2002; Hecht, 2004). 271
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Carcinogenicity
N-Nitrosonornicotine is reasonably anticipated 
to be a human carcinogen based on sufﬁ  cient 
evidence of carcinogenicity in experimental 
animals (Hecht, Carmella et al. 1993; Hoffmann, 
Brunnemann et al. 1994). N-nitrosonornicotine 
was shown to induce esophageal carcinomas and 
papillomas and carcinomas of the nasal cavity 
in rats of both sexes, nasal cavity adenocarci-
nomas in female rats, and papillomas of the nasal 
cavity and trachea in hamsters of both sexes 
(Hoffmann, Brunnemann et al. 1994) as well as 
epitheliomas and squamous cell carcinomas of 
the nasal cavity, and squamous cell carcinomas 
of the esophagus in male rats (Hoffmann, 
Rivenson et al. 1991; Hecht, Carmella et al. 
1993). Intraperitoneal injection of N-nitrosonor-
nicotine induced multiple pulmonary adenomas 
in mice of both sexes, lung adenomas in female 
mice, and nasal cavity tumors and tracheal 
papillomas in male hamsters (Hecht, 1997; 
Razani-Boroujerdi and Sopori, 2007). 
Exposure
N-Nitrosonornicotine has been found in a variety of 
tobacco products (chewing tobacco, snuff, cigarettes, 
and cigars), in mainstream and sidestream smoke from 
cigars and cigarettes, in saliva of chewers of betel 
quid with tobacco, and in saliva of oral-snuff users. 
Some of the N-nitrosonornicotine in saliva appears 
to be formed endogenously from nitrite in saliva and 
tobacco alkaloids. Thus, there is widespread exposure 
to N-nitrosonornicotine among users of tobacco 
products and those exposed to sidestream smoke. 
N-Nitrosonornicotine is reported to be produced by 
nitrosation of nicotine during the curing, ageing, 
processing, and smoking of tobacco. About half of 
the N-nitrosonornicotine originates in the unburnt 
tobacco, whereas the remainder is formed during 
burning. N-Nitrosonornicotine has been found in 
cigarettes at concentrations of 0.3 to 9 mg/kg, in snuff 
products at 12 to 29 mg/kg, in chewing tobacco at 
3.5 to 90.6 mg/kg, and in cigarette smoke at 0.14 
µg/cigarette (Preston-Martin, 1987; Hoffmann, 
Brunnemann et al. 1994; Brunnemann, Prokopczyk 
et al. 1996; Razani-Boroujerdi and Sopori, 2007)
Biological markers of tobacco 
exposure
Numerous methods exist to monitor tobacco smoke 
in experimental animals as well as in human 
populations. The simplest method the following 
tobacco exposure is by assessing either urinary or 
serum cotinine levels. Although this provides an 
accurate assessment of short-term exposure to 
tobacco, it fails to provide a long term assessment 
of exposure over several weeks and/or months. 
Additional methods of exposure to tobacco include 
measurement of levels of speciﬁ  c tobacco smoke 
compounds in both the urine and/or serum. Again 
that this method is limited on the fact that it is a 
short term assessment of tobacco exposure and is 
highly dependent upon the metabolic elimination 
parameters for each compounds and in each indi-
vidual. DNA adducts also provide effective means 
of monitoring exposure to tobacco smoke carcino-
gens. An ideal biomarker for use in assessing 
chemical exposures over a long-term basis is the 
Table 1. Tobacco speciﬁ  c nitrosamines and their carcinogenic rating according to the International Agency for 
Research on Cancer (Griciute, 1976; O’Neill and Fishbein, 1986; Preston-Martin, 1987).
Nitrosamine Abbreviation  Carcinogenicity
N-nitrosonornicotine  NNN  Group 2B IARC
4-(methylnitrosamino)-1-  NNK  Group 2B IARC
(3-pyridyl)-1-butanone 
4-(methylnitrosamino)-1-  NNAL  Group 2B IARC
(3-pyridyl)-1-butanol
N’-nitrosoanatabine  NAT  Group 3 IARC
N’-nitrosoanabasine  NAB  Group 3 IARC
4-(methylnitrosamino)-4-  NNA  Group 3 IARC
(3-pyridyl)butanal
4-(methylnitrosamino)-4- iso-NNAL 
(3-pyridyl)-1-butanol
4-(methylnitrosamino)-4- iso-NNAC
(3-pyridyl)butyric acid272
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use of the red cell protein hemoglobin. Hemoglobin 
not only serves his as a biomarker of exposure 
assessment, but also has a main function in the 
transport oxygen throughout the body into the 
various cells. Formation of electrophilic metabo-
lites of carcinogens has been shown to react with 
a variety of nucleophilic sites on hemoglobin, 
therefore forming covalent adducts which persists 
for the life of the red cell (120 days) and thus can 
be detected and used as a biomarker of exposure. 
Hemoglobin adducts originally were suggested as 
a biochemical monitor of carcinogen exposure and 
a measure of genotoxic risk by Ehrenberg, 
Osterman-Golkar and others (Osterman-Golkar, 
Kautiainen et al. 1991; Ehrenberg and Tornqvist, 
1992; Hecht, Carmella et al. 1993). Subsequentlly, 
a number of studies by several investigators. 
(Pastorelli, Guanci et al. 1999; Albertini, Sram 
et al. 2001; Jones, Liu et al. 2005; Beyerbach, 
Rothman et al. 2006; Ogawa, Oyama et al. 2006) 
have demonstrated that carcinogenic compounds, 
especially those present in cigarette smoke, bind 
covalently to hemoglobin. Hemoglobin presents 
itself as an ideal target for the interaction of various 
xenobiotics. Hemoglobin is relatively easy to 
obtain and the adducts of hemoglobin are stable 
adducts, unaffected by repair mechanisms that 
remove carcinogen adducts from DNA. Hemo-
globin, in the red cell, has a lifetime in the circula-
tion of approximately 120 days. Therefore, levels 
of hemoglobin adduct will accumulate in the circu-
lation, thus the detection of the adduct and allowing 
the use of hemoglobin as a biomonitor of exposure 
to various agents, such as those carcinogens found 
in tobacco smoke. 
Several reports have focused on the tobacco 
speciﬁ  c nitrosamine-DNA adducts in smokers and 
non-smokers in animal models using GC/MS and 
LC/MS-MS techniques (Lao et al. 2006; Guza et al. 
2006; Thomson et al. 2004). However, very few 
studies have been carried out studies investigating 
the formation of these biomarkers in a variety of 
classiﬁ  cations of smoking populations, including 
passively smoke exposed individuals, as well as 
maternal-fetal pairs (Hecht et al. 1991; Carmella 
et al. 1990). The majority of the methods that have 
been previously applied for the characterization of 
nitrosamine hemoglobin adducts involved a multi-
step process of extraction and chromatographic 
isolations prior to analysis utilizing GC/MS (Hecht, 
Carmella et al. 1991; Falter, Kutzer et al. 1994; 
Atawodi, Lea et al. 1998). These methods for the 
most part were extremely time-consuming, and 
had limited practicality and clinical situations 
where hundreds of samples are being run simulta-
neously. The goal of our study was to develop a 
new sensitive method which would involve simple 
extraction techniques without a chromatographic 
clean up prior to GC/MS operation.
Materials and methods
4-Hydroxy-1-(3-pyridyl)-1-butanone (HPB) and 
Deuterated  (3, 3, 4, 4-D4)HPB were purchased 
from Toronto Research Chemicals Inc., (North 
York, ON, Canada), and O-bis(Trimethylsilyl)-
triﬂ  uoroacetamide (BSTFA) was purchased from 
Pierce Biotechnology Inc., (Rockford, IL), 
2, 3, 4, 5, 6-Pentaﬂ  uorobenzoylchloride (PFBC) was 
purchased from Sigma-Aldrich Inc., (St Louis, 
MO). All additional chemical and solvents used 
throughout the experiments were of the highest 
grade commercially available.
Patient selection
Patients were selected from those admitted to labor 
and delivery at Norton’s Suburban Hospital and 
Norton’s Downtown Hospital and. In 2004, 
Norton’s Hospitals delivered approximately 4,000 
babies, placing it among the largest delivery centers 
in the metro Louisville area. The hospital’s popu-
lation admitted for labor and delivery consists of 
approximately 30% smokers, ranging from less 
than one pack per day smokers to greater than two 
packs per day smokers. During initial admission 
of the mother, 10 mL of blood was obtained using 
heparinized vautainers for measurement of 
hemoglobin adduct concentrations. Following 
delivery of the infant, 10 mL of blood was obtained 
from the umbilical cord for measurement of 
hemoglobin adduct concentrations. All samples 
were acquired using a University of Louisville 
approved institutional review Board protocol.
Maternal and fetal blood samples
Maternal blood samples were stratiﬁ  ed according 
to smoking status (nonsmokers, 1 pk/day, and >1 
pk/day). Samples were refrigerated immediately 
and stored until preparation of hemoglobin for 
analysis. Smoking status was assessed by detailed 
questionnaire as well as by measurement of plasma 
cotinine levels. Blood samples were centrifuged at 
3,000 xg for 10 minutes to generate packed red 273
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blood cells. Red cells were washed three times with 
0.9% saline and lysed by the addition of 15 mL ice 
cold deionized water with vigorous shaking. 
Cotinine assessment
Cotinine levels were measured by immunoassay 
(BioQuant, San Diego, CA). Stratiﬁ  cation of 
smokers into the smoking categories relied on 
cotinine assessments as well as questionnaire 
data. Non-smokers were judged as those women 
having cotinines less than 10 ng/mL, in accordance 
with previously published reports (Wagenknecht, 
Burke et al. 1992; McDonald, Perkins et al. 2005). 
Although widely used in epidemiological studies, 
self-report has been shown to underestimate the 
prevalence of cigarette smoking in some popula-
tions. In recent studies, self-report of cigarette 
smoking was validated against a biochemical 
marker of nicotine uptake, cotinine. The preva-
lence of smoking was slightly lower when deﬁ  ned 
by self-report (30.9%) than when deﬁ  ned by 
cotinine levels equal to or greater than 14 g/mL 
(32.2%, P < 0.05). The misclassiﬁ  cation rate 
(proportion of reported nonsmokers with cotinine 
levels of at least 10 ng/mL) was 4.2% and was 
signiﬁ  cantly higher among subjects who were 
African-American, had a high school education 
or less, or were reported former smokers. Possible 
reasons for misclassiﬁ  cation include reporting 
error, environmental tobacco smoke, and an inap-
propriate cutoff point for delineation of smoking 
status. Using self-report as the gold standard, the 
cotinine cutoff points that maximized sensitivity 
and speciﬁ  city were 14, 9, and 15 ng/mL for all, 
Caucasian, and African-American subjects, 
respectively. The misclassiﬁ  cation rate remained 
signiﬁ  cantly higher in African-American than in 
Caucasian subjects using these race-specific 
criteria. Misclassiﬁ  cation of cigarette smoking by 
self-report was low in these young adults; 
however, within certain race/education groups, 
self-report may underestimate smoking preva-
lence by up to 4%. 
Analysis of tobacco speciﬁ  c 
nitrosamine maternal and fetal 
hemoglobin adducts
Hemoglobin solutions (maternal and fetal), 5–8 
mls, corresponding to 4–6 mls blood were added 
to a 50 mL disposable borosilicate centrifuge tube. 
The normality of the solution was adjusted to 
0.15 N with 1N NaOH. The solution was sonically 
dispersed for 1 hour at room temperature and the 
pH of the solution was adjusted to pH 6–7 by the 
addition of 1N HCl. A solution of [4, 4-D2]HPB 
(150 fmol) in 10 µl water was added as the internal 
standard. The mixture was centrifuged at 2000–
3000 rpm for 10 minutes at room temperature and 
the supernatant was transferred with a Pasteur 
pipette to a second 50 mL centrifuge tube. The pH 
of the solution was adjusted to 1.5–2.5 by the addi-
tion of 1 N HCl and the solution extracted twice 
with equal volumes of dichloromethane and twice 
with equal volumes of hexane After discarding 
your organic extracts, the pH of the aqueous 
portion was adjusted to pH 6–7 with 1N NaOH, 
and was extracted three times with equal volumes 
of dichloromethane. The combined dichloro-
methane extracts were evaporated under reduced 
pressure and the residue was re-dissolved in 1 mL 
methanol, transferred to a small sample vial, and 
the methanol evaporated under nitrogen. 
Sample preparation HPB-hemoglobin 
adduct assay by GC/MS
100 µL lysed hemoglobin solutions were placed 
in a 7 mL borosilicate glass tube with screw cap 
telﬂ  on liner. 750 µL HPLC grade water and 150 µL 
1 N NaOH were added to the hemoglobin solution. 
10 µL of 2.5 µg/mL (3, 3, 4, 4-D4)HPB was added 
as the internal standard (IS). The solution was 
incubated in air at 50 
oC for 2 hours. Following 
incubation, the hemoglobin solution was acidiﬁ  ed 
by addition of 225 µL 1 N HCl, and washed by the 
addition of 2 mL dichloromethane and 2 mL 
n-hexane. The washed solution were neutralized 
by addition of 75 µL 1 N NaOH. After washing, 
the samples were extracted twice with 2 mL dichlo-
romethane, the extracts combined and dried under 
a gentle stream of nitrogen gas, and stored 
at –20 
oC.
Stock solutions of HPB and (3,  3,  4,  4-
D4)HPB were prepared in acetonitrile at concen-
trations of 1.25, 5.0, 12.5, 50.0, 125.0 and 500.0 
ng/mL. Trimethylsilyl derivatization of HPB 
and (3, 3, 4, 4-D4)HPB were prepared by the 
addition of 10 µL BSTFA and 30 µL acetonitrile 
to samples followed by incubation in air for 1 
hour at 60 °C. HPB-pentafluorobenzoate 
derivatization was performed by addition of 1 
µL PFBC in 49 µL n-hexane:triethylamine 274
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(50:1) followed by a 1 hour incubation in air at 
60 
oC. The derivatized samples were transferred 
to gas chromatographic and mass spectrometric 
sample vials and were diluted to a total volume 
of 100 µL with acetonitrile. Samples were 
analyzed in triplicate using both negative and 
positive chemical ionization modes as well as 
electron impact ionization modes and reported 
as pmoles HPB/gm Hb ± SEM.
GC/MS methods
A HP 6890 GC coupled to HP 5973 MS was 
interfaced with the Hewlett-Packard ChemSta-
tion software package for data acquisition and 
analysis. GC conditions were optimized with a 
temperature programming to attain the highest 
sensitivity and resolution. Helium carrier gas 
was used with a flow rate 1.3 mL/min. Gas 
chromatographic conditions included injection 
of samples using splitless injection mode with 
an injection port temperature at 280 
oC. A GC 
capillary column consisting of a DB-15MS with 
dimensions 15 m × 0.25 mm id × 0.25 µm film 
thickness (J&W Scientific, Folsom, CA). 
Samples were eluted through the GC column 
using a temperature program consisting of an 
initial temperature of 50 °C for one minute, 
followed by a ramp increase in temperature to 
230 °C at 20 °C/min, followed by a final 
isothermal temperature at 230 °C for five 
minutes.
Positive ion chemical ionization (PICI) 
Full scan (m/z 50–450) PICI mass spectral data   
(Table 2) were acquired to characterize deriva-
tized HPB and (3,  3,  4,  4-D4)HPB.  (3, 3, 4, 4-D4) 
HPB was used as internal standard (IS). Mass 
spectrometer conditions consisted of electron 
energy 221 eV, source temperature 250 
oC, emis-
sion current 237 µamp, and electron multiplier 
voltage 1718 V. Quantitation of trimethylsilyl 
derivative of HPB by BSTFA was performed 
using selected ion monitoring (SIM) at m/z 238 
and 242 for analyte and IS respectively. Pentaf-
luorobenzoate derivatized HPB by PFBC was also 
characterized using SIM at m/z 360 and 364 for 
analyte and IS respectively.
Negative ion chemical ionization (NICI)
Full scan (m/z 50–450) NICI mass spectral data 
(Table 3) were acquired to identify derivatized 
HPB  and  (3, 3, 4, 4-D4)HPB. Mass spectrometer 
conditions consisted of electron energy 193 eV, 
source temperature 150 
oC, emission current 49 
µamp, and electron multiplier voltage 2996 V. 
Quantitation of the trimethylsilyl derivative of 
HPB was performed using selec ted ion monitoring 
(SIM) at m/z 237 and 247 for analyte and IS respec-
tively. The HPB-pentaﬂ  uorobenzoate derivative 
was also characterized using SIM at m/z 359 and 
363 for analyte and IS respectively.
Electron impact ionization (EI)
Full spectrum (m/z 50–450) electron impact 
ionization (EI) mass spectral data (Table 4) were 
acquired to characterize derivatized HPB and 
(3, 3, 4, 4-D4)HPB. Electron impact ionization 
conditions included electron energy 70 eV, 
source temperature 230 
oC, emission current 35 
µamp, and electron multiplier voltage 1859 V. 
Quantification of derivatized HPB by BSTFA 
was performed using selected ions monitoring 
(SIM) at m/z 222 and 226 for analyte and IS 
respectively.
Table 2. Quantiﬁ  cation of HPB derivatized with BSTFA in maternal and Fetal cord blood samples using 
PICI mass spectrometry (mean ± SEM).
Smoking Status  Maternal    Maternal    Fetal     Fetal  
  (pmols HPB/  (pmols HPB/  (pmols HPB/  (pmols HPB/
  gm Hb)  gm Hb)  gm Hb)  gm Hb)
Non-Smokers (n = 45)  0.52 ± 0.22  0.42 ± 0.13  0.25 ± 0.13  0.13 ± 0.06 
Passively Exposed   2.16 ± 0.98  1.86 ± 0.35  1.31 ± 0.75  0.64 ± 0.35
(n = 26)          
<1 pack per day   5.24 ± 1.35  4.77 ± 0.68  2.16 ± 0.86  1.52 ± 0.74
smokers (n = 83)
>1 pack per day   12.65 ± 2.41  16.32 ± 1.16  6.52 ± 1.63  7.86 ± 1.55
smokers  (n  =  91)       275
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Results
Positive ion chemical ionization (PICI), negative 
ion chemical ionization (NICI) and electron impact 
ionization (EI) techniques were investigated 
to develop a sensitive gas chromatographic/mass 
spectrometry (GC/MS) procedure for the assessment 
of HPB (4-Hydroxy-1-(3-pyridyl)-1-butanone) 
released from hemoglobin adducts upon base 
catalyzed hydrolysis. Derivatization techniques 
using BSTFA (N,O-bis(Trimethylsilyl)-
trifluoroacetamide) and PFBC (2, 3, 4, 5, 6-
Pentaﬂ  uorobenzoylchloride) were also compared to 
improve the detection of HPB.
PICI is a soft ionization technique which gener-
ates a strong parent molecular ion along with rela-
tively few fragmentation ions. In PICI, the reagent 
gas is ionized by collision with emitted electrons 
from the electron source. The reagent gas ions then 
react chemically with the gas molecules obtained 
from the sample during volatilization to form posi-
tively charged molecular ion containing an extra 
proton [M+H]
+. A full scan m/z 50–450 PICI mass 
spectra for derivatized HPB by BSTFA was 
obtained by GC/MS and is illustrated in Figure 1, 
illustrating the molecular ions [M+H]
+ of 238 and 
m/z 222 which corresponds to [M-CH3]
+ whereas 
m/z 148 corresponds to the [M-OSi(CH3)3]
+ 
product.
Negative ion chemical ionization (NICI) is a 
relatively soft ionization technique which produces 
parent molecular ions with relatively limited 
fragmentation of the parent molecule. As was 
similar with positive ion chemical ionization, nega-
tive ion chemical ionization produces low energy 
thermal electrons. Sample molecules absorb these 
thermal electrons and thus form negatively charged 
molecular ions M
−. NICI is more sensitive than 
PICI because of lack of formation of negative 
reagent gas ions. A full scan m/z 50–450 NICI mass 
spectra for derivatized HPB by BSTFA was 
obtained by GC/MS is shown in Figure 2, illus-
trating the parent molecular ion of m/z 237 with 
limited fragmentary ions.
Electron impact ionization (EI) is a hard ioniza-
tion technique compared to either positive or nega-
tive chemical ionization modes and this technique 
generates relatively small amounts of parent 
molecular ions but considerably larger quantities 
Table 4. Quantiﬁ  cation of HPB derivatized with BSTFA in maternal and Fetal cord blood samples using EI mass 
spectrometry (mean ± SEM).
Smoking Status  Maternal    Maternal    Fetal     Fetal  
  (pmols HPB/  (pmols HPB/  (pmols HPB/  (pmols HPB/
  gm Hb)  gm Hb)  gm Hb)  gm Hb)
Non-Smokers (n = 45)  n.d.  n.d.   n.d.  n.d.
Passively Exposed  1.66 ± 2.33  2.15 ± 2.04  1.86 ± 1.32  1.89 ± 1.42
(n = 26)           
<1 pack per day  9.22 ± 6.24  7.29 ± 3.71  4.64 ± 2.88  3.94 ± 2.36
smokers (n = 83)
>1 pack per day   19.4 ± 12.36  17.3 ±  9.34  11.6 ± 7.82  12.7 ± 10.4
smokers (n = 91)           
Table 3. Quantiﬁ  cation of HPB derivatized with BSTFA in maternal and Fetal cord blood samples using NICI 
mass spectrometry (mean ± SEM).
Smoking Status  Maternal    Maternal    Fetal     Fetal
  (pmols HPB/  (pmols HPB/  (pmols HPB/  (pmols HPB/
  gm Hb)  gm Hb)  gm Hb)  gm Hb)
Non-Smokers (n = 45)  0.74 ± 0.36  0.63 ± 0.55  0.41 ± 0.25  0.36 ± 0.29 
Passively Exposed  2.88 ± 0.92  2.37 ± 1.53  1.55 ± 0.72  1.24 ± 0.85
(n = 26)
<1 pack per day   6.44 ± 2.43  5.72 ± 1.92  3.11 ± 1.44  2.79 ± 1.29
smokers (n = 83) 
>1 pack per day   15.23 ± 4.83  15.33 ± 6.22  5.16 ± 3.26  5.13 ± 2.78
smokers (n = 91)276
Myers and Ali
Biomarker Insights 2007:2
of molecular fragmentary ions. In this technique, 
the generation of both parent molecular ions and 
considerable fragmentary and patterns can be used 
to characterize not only chemical nature of the 
given unknown but also to some degree structural 
assignments. A full scan m/z 50–450 NICI mass 
spectra for derivatized HPB by BSTFA was 
obtained by GC/MS illustrating a molecular ion of 
molecular ion M
+. m/z of 237 and fragmentary ions 
of a base peak of m/z 222 [M-CH3] is shown in 
Figure 3.
Similar values of both maternal and fetal 
nitrosamine adducts were detected both and 
African-American as well as Caucasian popula-
Figure 1. Positive ion chemical ionization spectra of trimethylsilyl derivatized 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) isolated from maternal 
smokers blood (>1 pack/day) (A) compared to the spectra of authentic derivatized HPB shown in B.
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tions. The relationship between the formation of 
nitrosamine maternal adducts as well as fetal nitro-
samine adducts were found to the similar both 
ethnic diversities. Although the placenta is some-
times considered a barrier that protects the infant 
from exposures to exogenous chemicals and 
substances, it is clear that the placental linings are 
not effective in blocking the transfer of hazardous 
chemicals, including the chemical carcinogens 
found in tobacco, from the fetus. Approximately 
50% of maternal exposure to the tobacco speciﬁ  c 
nitrosamines was found to cross the placenta and 
he found adducted to fetal hemoglobin. Since there 
is no maternal or fetal transfer of blood this tends 
to indicate that either the parent nitrosamine has 
crossed into the fetal circulation via the placenta 
and become metabolized to reactive intermediates 
in the fetal tissue or a reactive metabolite of the 
Figure 2. Negative ion chemical ionization spectra of trimethylsilyl derivatized 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) isolated from 
maternal smokers blood (>1 pack/day) (A) compared to the spectra of authentic derivatized HPB shown in B.
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nitrosamines has been formed in the maternal 
component and crossed into the fetal circulation. 
Considering the reactivity of various selector ﬁ  les 
of chemical carcinogens, including nitrosamines, 
it is highly probable that the parent nitrosamine has 
crossed from the maternal component into the fetal 
component. These studies clearly demonstrate that 
fetal exposure to environmental carcinogens can 
occur as a result of maternal exposures during 
pregnancy. Although the samples were acquired at 
delivery, the study suggests that mothers and smoke 
during pregnancy are potentially exposing their 
unborn fetuses to carcinogenic as well as toxic 
chemicals even during the early stages of pregnancy 
Figure 3. Electron impact ionization spectra of trimethylsilyl derivatized 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) isolated from maternal 
smokers blood (>1 pack/day) (A) compared to the spectra of authentic derivatized HPB shown in B.
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as a result of crossing of these carcinogens through 
the placenta. Future studies will be directed at 
determining the relationships between maternal and 
fetal exposure to environmental as well as tobacco-
related carcinogens particularly in the early stages 
of pregnancy, particularly the ﬁ  rst trimester, where 
a greater activity of cell division, and organogenesis 
is occurring. In addition, feature studies will be 
directed at determining the relationship between 
both maternal and fetal exposure to tobacco related 
carcinogens of a variety of classes and a variety of 
ethnicities. These studies will include the determi-
nation of hemoglobin adducts in both maternal and 
fetal circulations, as well as the differentiation 
between phase 1 and phase 2 enzyme levels in both 
maternal and fetal tissues that are related to the vile 
activation as well as they to detoxiﬁ  cation of a 
variety of chemical carcinogens. Taken together 
these studies will add considerably to the informa-
tion available concerning hazardous effects of 
chemical carcinogens, including tobacco-related 
carcinogens, on pregnancy and neonatal develop-
ment.
Discussion
A comparative study for PICI, NICI and EI was 
performed to evaluate the suitability of GC/MS 
method for the detection of hemoglobin adducts 
to tobacco speciﬁ  c nitrosamines in human samples. 
The results indicate that both negative ion chemical 
ionization as well as positive ion chemical ioniza-
tion modes of detection and mass spectrometry 
provided greater sensitivity and detection of the 
released HBP from hemoglobin in both maternal 
and fetal samples. Both ionization techniques 
produce considerably less background noise as 
compared to electron impact mode of ionization 
and the signal-to-noise ratio in both maternal and 
fetal samples exceeded 20:1 in the chemical ioniza-
tion modes compared to 3:1 in the electron impact 
ionization modes. Although both negative ioniza-
tion as well as a positive ionization modes appear 
to be considerably more accurate and sensitive than 
the electron impact mode of ionization for the 
analysis of nitrosamine adducts of hemoglobin, the 
electron impact mode of ionization does afford 
beneﬁ  ts when compared to chemical ionization 
modes. Analysis of samples using electron impact 
mode of ionization allows the investigator to obtain 
not only parent molecular ions of both derivatized 
and non-derivatized samples, but also allows the 
obtaining of multiple fragmentary ions which can 
be used in structure elucidation and characteriza-
tion of unknown adducts.
Both HPB and (3, 3, 4, 4-D4) HPB were derivatized 
by BSTFA and PFBC separately to improve the 
sensitivity of the compounds. These agents are 
well-established chemicals used for enhancing 
detection of chemicals using gas chromatographic and 
mass spectral techniques and improve the detection 
sensitivity over the non-derivatized sample by 
approximately tenfold. In addition, the process of 
derivatization of the released HBP forms a highly 
volatile chemical that is easier to process and analyzed 
using the described gas chromatographic techniques. 
Both derivatization techniques utilizing both BSTF at 
a as well as PFBC enhanced selectivity and sensitivity 
of detection when compared to non-derivatized 
samples. BSTFA derivatives are characterized as 
trimethylsilyl products of the hydroxyl group of HPB. 
On the other hand, derivatives performed with PFBC 
are characterized as a pentaﬂ  uorobenzoate derivative 
of HPB. Comparative studies between the two 
derivatization techniques and among all three 
ionization techniques showed that the PFBC 
derivatives of HBP resulted in higher degree of 
sensitivity in the detection of both maternal and fetal 
nitrosamine hemoglobin adducts. 
This study demonstrates that upon a mild base 
hydrolysis HPB was released from lysed hemo-
globin obtained from smoking and non-smoking 
mothers and fetal cord blood. In addition, increasing 
levels of both maternal and fetal tobacco speciﬁ  c 
nitrosamines, as assessed via the detection of HBP 
released upon basic hydrolysis of hemoglobin, was 
found as smoking status increased from non-smokers 
to greater than one pack per day smokers. These 
studies indicate that mothers and smoke during 
pregnancy exposed the unborn fetus to compounds 
found in tobacco, including the tobacco speciﬁ  c 
nitrosamines, many of which have been shown to 
cause animal tumors and teratogenesis. This study 
strongly conﬁ  rms that the placenta does allow the 
passing of carcinogens, such as those found in 
tobacco, into the fetus. While the study was limited 
in the obtaining of maternal and fetal samples at 
term, this does not preclude that damage can in 
fact occurred to the developing fetus as a result of 
maternal smoking habits during pregnancy.
Previous studies determining smoking status in 
both individuals as well as during pregnancy has 
been limited in the past to determining either urinary 
or serum levels of a speciﬁ  c metabolite of nicotine 280
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found in biological fluids, namely cotinine. 
Numerous assays and reports have been published 
over the many years dealing with this biomarker of 
tobacco exposure and in large parts this is been an 
effective biological indicator of smoke exposure. 
However there are many limitations as to the appli-
cability and use of cotinine as a biomarker of 
tobacco exposure. One of the downsides of using 
cotinine as a speciﬁ  c biomarker of tobacco exposure 
is that the half-life of cotinine is relatively short in 
biological systems, approximately 24 hours. The 
use of cotinine alone as a biomarker of tobacco 
exposure can lead to conﬂ  icting results when one 
takes into consideration the potential of both long 
and protracted labor in childbirth. A more recent 
biological marker, such as that of using protein 
adducts of tobacco speciﬁ  c compounds provide a 
much clearer and much more precise assessment of 
current smoking status that is not interfered upon 
by use of half-life of cotinine. These results illustrate 
the applicability and use of hemoglobin as a 
biomarker of tobacco speciﬁ  c nitrosamines found 
in tobacco smoke. In addition, we have shown that 
the methods that are used allow both sensitive and 
accurate assessments of this biomarker in both 
maternal as well as in fetal blood samples taken at 
delivery. By assessing not only the maternal expo-
sure during pregnancy but also fetal exposures taken 
at the time of delivery we may be in better position 
to assess the potential harm of these compounds 
during fetal gestation and delivery.
Future studies will be directed at determining the 
efﬁ  cacy of various modes of detection for environ-
mental carcinogen adducts on hemoglobin, espe-
cially tobacco-related carcinogens, and the overall 
effect that these compounds have in the developing 
fetus. Speciﬁ  cally, we will be investigating early 
ﬁ  rst trimester exposure utilizing various biological 
markers such as hemoglobin adducts and amniotic 
ﬂ  uid samples as indicators of exposure to harmful 
chemicals early in pregnancy. By understanding the 
relationship between exposure assessment, biolog-
ical markers, and risk of potential disease, we may 
be in a better position to both predict and prevent 
the potential carcinogenic effects associated with 
maternal smoking during pregnancy.
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